Clinical Trial Update: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation study of ZFN genome editing (SB-318) in MPS I was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type

Drugs mentioned

• SB-318

Snippet

Sponsor: Sangamo Therapeutics | Conditions: MPS I | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-01-26